| scholarly article | Q13442814 |
| P50 | author | David C. Sousa | Q50135129 |
| P2093 | author name string | Miguel N Burnier | |
| Pablo Zoroquiain | |||
| Evangelina Esposito | |||
| Maria Eugenia Orellana | |||
| Ana Beatriz Dias | |||
| P2860 | cites work | Cell blocks in cytopathology: a review of preparative methods, utility in diagnosis and role in ancillary studies | Q38239059 |
| Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. | Q38291348 | ||
| Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets | Q38804169 | ||
| The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines | Q39244182 | ||
| Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms | Q40644774 | ||
| The effect of race on the incidence of retinoblastoma | Q43269243 | ||
| The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death | Q43286776 | ||
| Expression and amplification of therapeutic target genes in retinoblastoma | Q45153930 | ||
| Prognostıc value of increased HER2 expression in cancers of pancreas and biliary tree | Q51075580 | ||
| Retinoblastoma | Q58347703 | ||
| Retinoblastoma | Q58347781 | ||
| HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications | Q78516471 | ||
| What makes a good drug target? | Q82880925 | ||
| Expression of SIRT2 and SIRT6 in retinoblastoma | Q86689513 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study | Q33913521 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| Biology of HER2 and its importance in breast cancer | Q34428745 | ||
| Treatment of Retinoblastoma in 2015: Agreement and Disagreement | Q35778270 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| HER2/ERBB2 immunoreactivity in human retinoblastoma. | Q36923901 | ||
| Incidence of retinoblastoma in the USA: 1975-2004. | Q37214218 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| HER2-positive gastric cancer | Q37468290 | ||
| Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy | Q37707899 | ||
| Treatment of HER2-overexpressing breast cancer | Q37799950 | ||
| Truncated HER2: implications for HER2-targeted therapeutics | Q37894315 | ||
| Treatment of HER2-positive breast cancer: current status and future perspectives. | Q37962332 | ||
| Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. | Q38087507 | ||
| P433 | issue | 3 | |
| P921 | main subject | retinoblastoma | Q500695 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 210-215 | |
| P577 | publication date | 2017-02-23 | |
| P1433 | published in | Ocular oncology and pathology | Q27726435 |
| P1476 | title | HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target? | |
| P478 | volume | 3 |
| Q90682504 | In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina | cites work | P2860 |
Search more.